Zeria To Distribute Cortecs' H Pylori Test In Japan

30 July 1997

- Cortecs' point-of-care diagnostic for Helicobacter pylori infectionwill be distributed in Japan, under the trade name Helitest, by Zeria Pharmaceuticals, a major player in the Japanese peptic ulcer market. Helitest was approved in Japan on June 10, and initial shipments are scheduled for this month. Zeria was signed up by Zenyaku Kogyo, which holds the Japanese license for the product.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight